The Mechanism of Circulating Tumor Cell (CTC) Detection
DOI:
https://doi.org/10.61173/j4pyz373Keywords:
-Component, Circulating Tumor Cells (CTCs), Surface Protein Detection, miRNA-based Detec-tion, Combined Multi-Marker DetectionAbstract
The high lethality of cancer is mainly attributed to its metastatic ability. Circulating tumor cells (CTCs), as important mediators driving tumor metastasis, have significant research value in tumor progression and prognosis assessment. In recent years, CTC detection methods have been continuously evolving, mainly including detection based on cell surface proteins and detection based on intracellular miRNA molecular markers. Surface protein detection techniques are mature and high-throughput, but prone to missed detections when epithelial-mesenchymal transition (EMT) causes phenotypic changes; miRNA detection, on the other hand, can dynamically reflect the status of tumor cells, with high sensitivity, yet the process is complex and difficult to apply on a large scale. Currently, capturing the phenotypically heterogeneous and rare CTCs accurately remains a challenge in the field of detection. This paper systematically analyzes the principles, methods, current applications, and respective issues of the two major classes of CTC detection technologies: miRNA and surface protein detection. Furthermore, it discusses the positive role of combined detection in enhancing detection sensitivity and accuracy. Studies indicate that multi-marker combined detection can more comprehensively identify CTC heterogeneity, aiding in early tumor diagnosis, dynamic monitoring, and precise treatment. This paper provides a reference for the optimization of subsequent CTC detection technologies and in-depth research on tumor metastasis mechanisms, while pointing out current deficiencies in standardization, automation, and functional status analysis. Future research may focus on directions such as multi-omics integration and intelligent analysis.
References
[1] D. Ribatti, R. Tamma, and T. Annese, “Epithelial- Mesenchymal transition in cancer: A historical overview,” Translational Oncology, vol. 13, no. 6, p. 100773, 2020.
[2] X. Gu, S. Wei, and X. Lv, “Circulating tumor cells: from new biological insights to clinical practice,” Signal Transduction and Targeted Therapy, vol. 9, no. 1, 2024.
[3] M. N. Le et al., “Investigating surface proteins and antibody combinations for detecting circulating tumor cells of various sarcomas,” Scientific Reports, vol. 14, no. 1, 2024.
[4] L. Hu et al., “Enrichment and detection of circulating tumor cells by immunomagnetic beads and flow cytometry,” Biotechnology Letters, vol. 43, no. 1, pp. 25–34, 2020.
[5] M. Vidlarova et al., “Recent advances in methods for Dean&Francis ISSN 2959-409X circulating tumor cell detection,” International Journal of Molecular Sciences, vol. 24, no. 4, p. 3902, 2023.
[6] C. Chen, “Real-time quantification of microRNAs by stemloop RT-PCR,” Nucleic Acids Research, vol. 33, no. 20, p. e179, 2005.
[7] Chinese Academy of Sciences, “Scientists propose new strategy for in situ detection of multiple mIRNAs in single circulating tumor cells,” [Online]. Available: https://english.cas. cn/newsroom/research_news/life/202208/t20220824_312866. shtml
[8] H. Zhao et al., “The CRISPR-Cas13a Gemini System for noncontiguous target RNA activation,” Nature Communications, vol. 15, no. 1, 2024.
[9] B. Humphries and C. Yang, “The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy,” Oncotarget, vol. 6, no. 9, pp. 6472– 6498, 2015.
[10] X. Shi et al., “Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives,” Signal Transduction and Targeted Therapy, vol. 9, no. 1, 2024.
[11] V. P. Dave et al., “MicroRNA amplification and detection technologies: opportunities and challenges for point of care diagnostics,” Laboratory Investigation, vol. 99, no. 4, pp. 452– 469, 2018.
[12] K. Kang, X. Peng, J. Luo, and D. Gou, “Identification of circulating miRNA biomarkers based on global quantitative real-time PCR profiling,” Journal of Animal Science and Biotechnology, vol. 3, no. 1, 2012.
[13] S. Antolín et al., “Circulating miR-200c and miR-141 and outcomes in patients with breast cancer,” BMC Cancer, vol. 15, no. 1, 2015.
[14] X. Wu, X. Cui, C. Yue, X. Liu, and Z. Mo, “Expression of miR-92a in colon cancer tissues and its correlation with clinicopathologic features and prognosis,” American Journal of Translational Research, vol. 13, no. 8, pp. 9627–9632, 2021.
[15] J. Hou, F. Meng, L. W. C. Chan, W. C. S. Cho, and S. C. C. Wong, “Circulating plasma MicroRNAs as diagnostic markers for NSCLC,” Frontiers in Genetics, vol. 7, 2016.
[16] K. Felekkis and C. Papaneophytou, “Challenges in using circulating Micro-RNAs as biomarkers for cardiovascular diseases,” International Journal of Molecular Sciences, vol. 21, no. 2, p. 561, 2020.
[17] S. Dierks et al., “Comparison and harmonization of different semi-automated and automated QRT-PCR assays in the assessment of SARS-COV-2,” Viruses, vol. 14, no. 10, p. 2239, 2022.
[18] Y. I. Petrova, L. Schecterson, and B. M. Gumbiner, “Roles for E-cadherin cell surface regulation in cancer,” Molecular Biology of the Cell, vol. 27, no. 21, pp. 3233–3244, 2016.
[19] S. Dimitriadis et al., “Imaging flow cytometry: development, present applications, and future challenges,” Methods and Protocols, vol. 7, no. 2, p. 28, 2024.
[20] A. Muchlińska, J. Smentoch, A. J. Żaczek, and N. Bednarz- Knoll, “Detection and characterization of circulating tumor cells using imaging flow cytometry—A perspective study,” Cancers, vol. 14, no. 17, p. 4178, 2022.
[21] A. Muchlińska et al., “Improved characterization of circulating tumor cells and cancer-associated fibroblasts in one-tube assay in breast cancer patients using imaging flow cytometry,” Cancers, vol. 15, no. 16, p. 4169, 2023.
[22] Q. Zhang et al., “A detachable magnetic nanodevice for the efficient capture and subtype identification of circulating tumor cells,” Advanced Functional Materials, vol. 34, no. 36, 2024.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
